News / US / cnbc
UBS Boosts JNJ Price Target as Healthcare Giant Eyes Sustained Growth
Health Technology · Pharmaceuticals: Major · cnbc · 2026-09-02
.SPX, JNJ, UBS, IYH, IHE, MRK, NVS, ISRG
Analysts at UBS have raised their price target on Johnson & Johnson to $320, citing strong oncology growth and a favorable outlook for its drug pipeline.
What Happened
Bullish Analyst Outlook: UBS analysts recently increased their price target for Johnson & Johnson to $320, driven by expectations of an accelerated top-line growth rate exceeding 8% through the end of the decade. The firm highlights JNJ's transition back into a growth stock, supported by a strategic shift toward higher-margin product offerings.
Oncology Portfolio Strength: The company's cancer drug Darzalex remains a cornerstone of its success, with analysts projecting peak annual sales between $22 billion and $23 billion. UBS emphasizes that the drug faces a gradual revenue decline rather than a sudden patent cliff, ensuring it remains a dominant standard of care for multiple myeloma.
Pipeline and Innovation Drivers: Beyond oncology, the immunology franchise featuring Tremfya continues to show rapid expansion, with recent quarterly sales surging by 71%. Furthermore, the successful launch of Icotyde and the potential market entry of the Ottava robotic surgery system are viewed as significant long-term revenue catalysts.
Market Performance Context: Johnson & Johnson has outperformed the broader S&P 500 with a 33% year-to-date gain, reflecting a broader investor rotation into defensive healthcare stocks. Analysts view the company as one of the cleanest large-cap pharmaceutical stories due to its lack of binary risks and strong fundamental growth profile.